Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for cardioprotection in chronic myeloid leukemia patients receiving nilotinib or dasatinib
IRCT20241013063353N1Phase 3Recruiting
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of carvedilol in chronic myelogenous leukemia (CML) (2 arms), sponsored by Mazandaran University of Medical Sciences. Primary endpoints: Left ventricular ejection fraction, Pro-BNP and 13 more. Started Feb 2026; status: recruiting.
02
Drugs
carvedilol
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on IRCT20241013063353N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20241013063353N1.